• KYMRIAH: CAR T-Cell Therapy for Relapsed ALL

    Dana-Farber/Boston Children's is a certified treatment center for providing the recently FDA-approved CAR T-cell therapy called KYMRIAH to patients who are up to 25 years old with second or later relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

    What is CAR T-cell therapy?

    CAR (chimeric antigen receptor) T-cell therapy is a promising new treatment for some of the most challenging cases we face in pediatric ALL. It works by modifying the body's T-cells, a type of immune system cell that hunts and destroys abnormal cells, such as cancer cells.

    To do so, the patient's own T-cells are collected intravenously through a process called apheresis. Once collected, the T-cells are genetically engineered to specifically target a protein called CD19 that is present on the surface of the leukemia cells.

    These genetically-engineered cells are then reinfused to the patient via an intravenous line. After returning to the patient's body, the CAR T-cells systematically target and kill the CD19-expressing leukemia cells in the body.


     

    Why choose us for CAR T-Cell Therapy

    Dana-Farber/Boston Children's is one of the top pediatric leukemia treatment programs in the world. Our Hematologic Malignancy Center has been a leader in advancing treatment of childhood ALL, which has resulted in an overall 90 percent cure rate for the disease. To increase the cure rate, our leukemia specialists continue to pioneer the latest and most innovative treatments through clinical trials and experimental therapeutics.

    To offer KYMRIAH to eligible patients, our CAR T-cell therapy team is made up of experts in leukemia, gene therapy and stem cell transplantation. This team is built upon a world-leading gene therapy program, one of the country's largest stem cell transplant centers and is supported by the #1-ranked children's hospital by U.S. News & World Report.

    Our team is experienced in administering genetically-modified therapies and is well equipped to anticipate and handle any potential side effects of CAR T-cell therapy. In addition to CAR T-cell therapy, we also have experience in treating patients with intravenous gene therapies for adrenoleukodystrophy, X-linked severe combined immunodeficiency, Wiskott-Aldrich syndrome, chronic granulomatous disease and more.

    Learn more about the CAR T-cell therapy team.

    Who is eligible for KYMRIAH?

    KYMRIAH is indicated for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse. You and your care team will decide if this treatment is right for your child.

    Get answers to frequently asked questions about KYMRIAH and CAR T-Cell Therapy.

    The CAR T-cell Therapy Process

    Click to see an infographic about the CAR T-cell therapy process:

    infographic on the CAR T-cell therapy process

    Additional Resources

    Our gene therapy news
    Our gene therapy program
    More information on relapsed ALL

    For more information about whether KYMRIAH is right for your child or to refer a patient, contact:
    Colleen Dansereau, RN
    Gene Therapy Program Manager
    Phone: 617-919-7008
    Email: colleen.dansereau@childrens.harvard.edu